Determination and clinical features of bone pseudoprogression in metastatic breast cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.New osteoblastic lesions in breast cancer bone metastasis may indicate pseudoprogression, not disease progression. Alkaline phosphatase (ALP) levels can help differentiate these conditions, guiding treatment decisions.
Area Of Science
- Oncology
- Radiology
- Biochemistry
Background
- Bone is a common site for breast cancer metastasis.
- Distinguishing new osteoblastic lesions from true disease progression is challenging.
- Computed tomography (CT) with bone window settings is standard for evaluating bone metastases.
Purpose Of The Study
- To assess the clinical features of bone pseudoprogression in metastatic breast cancer (MBC).
- To evaluate the significance of new osteoblastic lesions during treatment.
- To identify biomarkers for differentiating pseudoprogression from disease progression.
Main Methods
- Retrospective analysis of 23 MBC patients with new osteoblastic lesions during first-line therapy.
- Treatment response assessed via CT (bone window) every two cycles.
- Alkaline phosphatase (ALP) levels analyzed at pseudoprogression and disease progression.
Main Results
- New osteoblastic lesions were identified as bone pseudoprogression in the absence of explicit progression.
- The median interval between pseudoprogression and actual disease progression was 14.27 months.
- Decreased or stabilized ALP levels at pseudoprogression contrasted with increased levels at disease progression (p<0.001).
Conclusions
- New osteoblastic lesions on CT (bone window) can represent pseudoprogression, especially early in treatment.
- Alkaline phosphatase (ALP) is a potential biomarker to differentiate pseudoprogression from true progression.
- Caution is advised when interpreting new osteoblastic lesions without other signs of disease advancement.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
